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Abstract.  The cytoadhesins represent a  group of RGD 
receptors that belongs to the integrin superfamily of 
adhesion molecules. Members of this cytoadhesin fam- 
ily include the platelet GPIIb-IIIa and the vitronectin 
receptors.  These glycoproteins share the same/~-sub- 
unit, which is associated with different ot subunits to 
form an a/[3 heterodimer. In the present study, we 
have analyzed the fine recognition specificity of the 
cytoadhesins from platelets and endothelial cells for 
the adhesive protein, fibrinogen. Two sets of synthetic 
peptides,  RGDX peptides and peptides corresponding 
to the COOH terminus of the fibrinogen 3' chain, were 
compared for their structure-function relationships in 
the two cellular systems. The results indicate that:  (a) 
both RGDX and 3'-chain peptides inhibit the binding 
of fibrinogen to platelets and endothelial cells; (b) a 
marked influence of the residue at the COOH- and 
NH2-terminal positions of each peptide set can be 
demonstrated on the two cell types; and (c) RGDX 
and "t peptides have differential effects on platelets and 
endothelial cells with respect to fine structural require- 
ments. These results clearly indicate that while the 
platelet and endothelial cytoadhesins may interact with 
similar peptidic sequences, they express a  different 
fine structural recognition. 
M 
EMBERS of a  broadly distributed  superfamily of 
adhesion receptors,  which have been termed the 
integrins (23), mediate a wide variety of cell-cell 
and cell-substrata  interactions.  This  superfamily is  com- 
prised of noncovalent heterodimers, and the a and/3 subunits 
of each heterodimer contain membrane-spanning domains. 
Three distinct groups of adhesion receptors,  with specific 
structural and functional features have  already been iden- 
tified within the integrin superfamily: (a) the Leu-CAM fam- 
ily which is found on leukocytes and includes LFA-1, MAC-l, 
and p150,95 (48); (b) the VLA family, of which there are at 
least five distinct members that are found on a variety of cell 
types, including the fibronectin receptor from fibroblasts (21, 
50); and (c) the cytoadhesin family (16, 39, 40).  Members 
of the cytoadhesin family include GPIIb-IIIa from platelets 
and megakaryocytes and the vitronectin receptors, which are 
found on endothelial (15), melanoma (5), and osteosarcoma 
(41) cells. Members of each family have a similar/3 subunit, 
which associates with different a  subunits to create function- 
ally distinct adhesion receptors.  Thus, the platelet and the en- 
dothelial cell cytoadhesin share a similar/3 subunit, GPIIIa, 
but distinct a  subunits (15). The three/3 subunits, one from 
each family, are highly related to one another,  exhibiting 
40-50% identity at the amino acid sequence level (5, 11, 26). 
Certain members of the cytoadhesin family exhibit recog- 
nition specificity that permits them to interact with more than 
a  single  adhesive protein.  For  instance,  GPIIb-IIIa from 
platelets  can  interact  with  at  least  three  adhesive  pro- 
teins-fibrinogen (1, 31), von Willebrand factor (12, 45), and 
fibronectin (13, 33)-and the cytoadhesins from endothelial 
cells have been shown to mediate the attachment of these 
cells to vitronectin, fibrinogen, and von Willebrand factor 
(2-4, 6, 7). Considerable progress has been made in defining 
the fine recognition specificities involved in the binding of 
the various adhesive proteins to GPIIb-IIIa. Specifically, an 
Arg-Gly-Asp (RGD) recognition is involved in these interac- 
tions since RGD-containing peptides inhibit the binding of 
all three adhesive ligands to GPIIb-IIIa (14, 19, 38, 43). The 
RGD recognition specificity is not restricted to the cytoadhe- 
sin family but is also involved in the recognition of extracel- 
lular ligands by certain members of the other two families 
within the integrin superfamily (42, 49). In addition, a sec- 
ond recognition specificity has been implicated in the bind- 
ing of adhesive proteins to GPIIb-IIIa; these interactions can 
be inhibited by a second peptide set that corresponds in se- 
quence to the extreme COOH terminus of the 3' chain of fi- 
brinogen.  This sequence of 3" 400-411  is HHLGGAKQA- 
GDV (20, 37). Despite these indications of a relaxed recog- 
nition specificity of GPIIb-IIIa, the RGD and 3"-chain pep- 
tides inhibit the binding of the recognized adhesive proteins 
to platelets with a  fine structural specificity. For example, 
conservative amino acid substitutions at the Arg, Gly, or Asp 
position markedly diminish the potency of the peptides as in- 
hibitors of ligand binding (46).  Similarly, acetylation of the 
©  The Rockefeller  University  Press,  0021-9525/89/06/2519/9  $2.00 
The Journal of Cell Biology,  Volume  108, June  1989 2519-2527  2519 Lys residue within the -y-chain peptide renders it inactive in 
inhibiting ligand binding to platelets (27, 28). In contrast to 
this detailed information on the recognition specificity of 
GPIIb-IIIa, only limited data are available on the recognition 
specificity of the endothelial cell cytoadhesin. RGDS has 
been shown to interfere with the attachment of these cells to 
fibrinogen and other adhesive proteins, and a monoclonal an- 
tibody that inhibits fibrinogen binding to platelets also in- 
hibits endothelial cell attachment to fibrinogen (2, 4). 
With the ability to quantitatively analyze the binding of 
fibrinogen to endothelial cells and the evidence that this in- 
teraction is mediated by the endothelial cell cytoadhesin, it 
is now possible to dissect the fine recognition specificity of 
the cytoadhesin from these cells for fibrinogen and compare 
it to that of platelets.  Such an analysis has been undertaken 
in this study. 
Materials and Methods 
Proteins and Synthetic Peptides 
Human fibrinogen was purified by differential ether fractionation and was 
radiolabeled with carrier-free Nat25I  (Amersham International, Bucking- 
hamshire, England) to a specific activity of 1 #Ci/p-g by a modified chlora- 
mine T  (Eastman Kodak Co.,  Rochester, NY)  procedure,  as previously 
described (31). The purity of the protein, including its freedom from con- 
taminating plasminogen, thrombin, factor VIII, von Willebrand factor,  and 
fibronectin has already been detailed (31). Contaminating fibronectin was 
reduced to a trace amount by affinity chromatography on gelatin Sepharose 
and never exceeded 5-10 ~g fibronectin/mg fibrinogen (29). 
Human fibronectin was purified from human plasma by affinity chroma- 
tography on gelatin Sepharose, as previously described (10). The purity and 
the integrity of the protein was verified by SDS-PAGE. 
Synthetic peptides were prepared by the solid phase method, described 
by Merrifield (32),  using a  synthesizer (Peptomat, Sherbrooke, Canada) 
with Merrifield resins and t-Boc-amino acids (Fluka AG, Buchs, Switzer- 
land). The first amino acid was attached to the resin by the Merrifield proce- 
dure (32) or the Gisin method (17). The general synthesis protocol used was 
the following: 40% TCA and 0.10% acetyl-D-L-tryptophan in dichlorometh- 
ane for deprotection, 5 % N-ethyldiisopropylamine in dichloromethane for 
neutralization, and two- or threefold excess oft-Boc-amino acids with direct 
N-N'-dicyclohexylcarbodiimide/1-hydroxy-benzatriazol coupling,  for 2  h. 
The completeness of coupling and deprotection was estimated according to 
the test by Kaiser et al. (25), and each coupling was followed by an acetyla- 
tion with acetic anhydride.  Protecting groups and the peptide-resin link 
were cleaved with liquid HF-anisole (Interchim) (reference 10; 1 vol/vol) for 
1 h at 0°C. After evaporation of HF the resin was washed with anhydrous 
diethylether. Crude peptides were extracted with  10-45%  acetic acid ac- 
cording to their hydrophobicity and freeze-dried twice. Peptides were first 
purified by gel filtration on Sephadex GI0. The amino acid composition was 
verified by amino acid analysis using an alpha analyzer (LKB Instruments 
Inc., Stockholm, Sweden) and was consistent with the sequence of the pep- 
tides. The homogeneity of the peptides was verified by analytical reverse- 
phase HPLC, using a C18-ODS 2 column with a 0-80% linear gradient of 
acetonitrile in 0.1% trifluoroacetic acid. Peptides were generally 95%  ho- 
mogenous and, if not, they were purified by preparative HPLC. 
Cells 
Platelets were isolated from fresh human blood drawn into acid-citrate- 
dextrose by differential centrifugation followed by gel filtration in a modified 
Tyrode's buffer,  pH 7.2,  containing 2% BSA (31). To avoid the formation 
of microaggregates, 0.1  #M PGE~  was maintained throughout the proce- 
dure and was removed from the platelet suspension during the gel filtration 
on Sepharose CL 2B. 
Human endothelial cells were obtained from human umbilical veins ac- 
cording to the method of Jaff6 et al.  (24).  Optimal plating efficiency and 
growth rate of endothelial cells were obtained when cells were seeded on 
fibronectin matrices (30). Thus, petri dishes were coated as follows: 2 ml 
of a 0.25-mg/ml fibronectin solution in Hanks' buffered saline (HBS) con- 
taining 2 M urea were deposited on petri dishes (Falcon Labware, Oxnard, 
CA) under laminar flow hoods for 20 min at 37°C. The fibronectin solution 
was removed from the dishes and the cells were plated at a  105-cells/ml 
density and cultured in medium  199 containing 30%  pooled serum,  100 
U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine.  Endothelial 
cells were passaged by incubating the cells with either HBS/0.05%  EDTA 
or HBS/0.OI% EDTA, 0.1% trypsin (Boehringer Mannheim GmbH, Mann- 
helm, FRG). Control experiments indicated that both detachment proce- 
dures gave the same results. For example, the binding of 125I-fibrinogen 
and endothelial cell adhesion was identical when detachment was performed 
in the presence of EDTA alone or EDTA plus trypsin. 
For binding experiments, cells obtained from the second or third passage 
were washed three times with PBS, pH 7.3, containing trypsin inhibitor (0.1 
mg/ml) and resuspended in the binding buffer. 
Binding Assays 
Binding of fibrinogen to platelets and its inhibition by various peptides were 
performed as previously described (31). Briefly, platelets at a final concen- 
tration of 2  ×  108 cells/ml were incubated with 1~sI-fibrinogen, at a final 
concentration of 0.1 p-M, and varying concentrations of peptides. The bind- 
ing reaction was initiated by the addition of 5 p-M ADP in the presence of 
0.5  mM CaClz, and the interaction was quantified after 30 rain at room 
temperature by separating bound from free ligands by centrifugation of 50- 
p-l aliquots of the reaction mixture through 20%  sucrose. Interaction of 
fibrinogen with endothelial cells was performed with cells in suspension. 
Briefly,  2  ×  106 cells/ml were  resuspended in  PBS,  2%  BSA,  l  mM 
CaCI2,  1 mM MgCl2, and 1251-fibrinogen was added at a final concentra- 
tion of 0.04 p-M. After 3 h at 37°C,  IZSI-fibrinogen bound to cells in the 
presence or absence of the selected peptides was measured. Nonspecific 
binding was evaluated  by measuring 1251-fibrinogen  binding in the presence 
of a large excess of unlabeled fibrinogen (20 p.M). The inhibitory capacity 
of the peptides was expressed as the IC50 value,  the concentration which 
produced 50%  inhibition of specific binding. 
In parallel experiments, the viability of the cells was controlled by (a) 
dye exclusion procedure with fluorescein (44) for viable cells and ethidium 
bromide for dead cells; and (b) the ability of the cells to attach and spread 
under various conditions. In all experiments it was observed that after 3 h 
of incubation, the viability of the cells ranged from 80 to 90%, and •85  _+ 
10%  of the cells readhered and respread. 
In control experiments, it was verified that the viability of the cells in 
the presence of the peptides was unaffected as shown by the dye exclusion 
procedure. Other experiments were performed to determine if the different 
peptides were hydrolyzed by endothelial cells or by platelets. For these con- 
trol experiments, the peptides were incubated for 3 h with either platelets 
or endothelial cells, the cells were centrifuged, the supernatant was treated 
with 15% TCA, and the soluble peptides were analyzed by HPLC. These 
controls indicated that none of the peptides tested were hydrolyzed by the 
cells during the time of the assay. 
Functional Assays 
Platelet aggregation was performed using washed platelets. Platelets were 
isolated from human blood drawn into acid-citrate-dextrose by differential 
centrifugation followed by gel filtration in a  modified Tyrode's buffer or 
medium  199, both containing 2%  BSA. Aggregation was measured in a 
dual-channel aggregometer (Model  800B;  Payton  Scientific Inc.,  Scar- 
borough, Ontario, Canada) at 37°C at a stirring rate of 1,000 rpm. The reac- 
tion mixture consisted of 400 #1 buffer,  10 p-I solution of synthetic peptides, 
10 p-1 CaCI2  (1  mM final  concentration),  10 p-I fibrinogen (0.5  ttM final 
concentration), and  10 p-I ADP (5 #M final  concentration). 
For adhesion assays, endothelial cells were labeled for 48 h with tritiated 
thymidine (0.2  p-Ci/ml)  (Amersham International).  Confluent cells were 
detached as described above and resuspended in medium 199 containing 2 % 
BSA. Petri dishes were coated with purifed fibrinogen at 0.25 mg/ml. The 
fibrinogen concentration on the plastic was determined using the radiola- 
beled protein as a tracer and was 8 p-g/cm  z.  1 ml of radiolabeled cells was 
seeded in petri dishes, and attachment was measured in the presence of vari- 
ous concentrations of peptides after  120 min at 22°C.  Each peptide was 
tested in triplicate with several different preparations of endothelial cells. 
The spreading was estimated on a four-point scale ranging from rounded 
cells (0) to extensive spreading (++++).  The scale was based on double 
immunofluorescent localization of actin (see Results). 
Double Immunofluorescent Localization of  Actin 
Human antiactin was a gift of Dr.  Micouin, from the Blood Center of Gre- 
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Binding of  Fibrinogen to ADP-stimulated Platelets 
and to Endothelial Cells 
IC50 
Peptides  Platelets  Endothelial  cells 
/~M  /zM 
RGD  > 1,000  > 1,000 
RGDS  (Fn,  vWF,  Fg)  55  _+  20  200  +  60 
RGDQ  (Csbi)  45  +  10  >1,000 
RGDC  (Pro-vWF)  35  +  10  320  +  20 
RGDV  (Vn)  18  +  7  350  +  20 
RGDF  (Fg)  9  +  3  150  +  50 
NIMEILRGDF  (Fg)  160  +  70  40  +  5 
ILRGDFSSAN  (Fg)  >500  50  +  5 
Platelets were stimulated with 5 ~tM ADP. The results are the mean value of 
three separate experiments. Each peptide  corresponds to a naturally occurring 
sequence within the structure of adhesive proteins:  (Fn,  fibronectin;  Fg,  fi- 
brinogen; vWF, von Willebrand Factor;  Vn,  vitronectin; and C,bi,  activated 
complement factor C3b. The single letter amino acids are as follows: R, argi- 
nine; G, glycine; D, aspartic acid;  S, serine; Q, glutamine; C, cysteine; V, va- 
line; F, phenylalanine; L, leucine; A, alanine; 1, isoleucine; N, asparagine; M, 
methionine. 
noble.  The cells were detached,  resuspended in serum-free medium 199 
containing 2% albumin, and seeded on fibrinogen-coated coverslips in the 
presence of various peptide concentrations as described for adhesion assays. 
Immunofluorescent localization of actin in cells was carried out according 
to a  modified method of Granger and Lazarid6s (18).  Briefly,  cells were 
washed three times with PBS at 37°C and then immersed in 3.7 % formalde- 
hyde in PBS at 37°C for  10 min. Cell permeation to antibodies was per- 
formed by dipping the coverslips for 5 min in a  solution containing 0.5% 
Triton X-100 in PBS. The antiactin solution was added to coverslips during 
30 min at 37°C. The cells were then washed for 15 min with the Triton-PBS 
buffer. The fluorescein conjugated Fab~' fragments of goat anti-human IgG 
(The Jackson Laboratory, Bar Harbor, ME) were deposited during 30 min 
at 37°C.  Finally, the cells were washed for  15 min and mounted in 50% 
glycerol-PBS. Observations were carried out with a photomicroscope (Rei- 
chert Jung, Vienna, Austria) equipped for epifluorescence. Fluorescence 
images were recorded on AGFA film, 400 ASA, and developed with T. MAX 
(Eastman Kodak Co.). 
Results 
The Effects of RGD Peptides 
The involvement of an RGD recognition specificity in ligand- 
receptor interactions has been demonstrated by the capacity 
of RGDX (where X can be one or several permissive amino 
acid substitutions) peptides to interfere with binding of the 
ligand to the receptor. To define more precisely the RGD rec- 
ognition  specificity involved in  mediating  the  binding  of 
fibrinogen to endothelial cells, a  series of RGDX peptides 
was synthesized and their capacity to inhibit the interaction 
of fibrinogen with these cells was examined. The effect of 
these peptides on fibrinogen binding to platelets was  ana- 
lyzed in parallel experiments to permit comparison of the 
recognition  specificities of the  two  cells.  With  both  cell 
types, the RGD tripeptide was ineffective  since it did not pro- 
duce detectable inhibition of fibrinogen binding at a  1-mM 
concentration  (Table  I).  Thus,  the  three-amino  acid  se- 
quence is not sufficient to inhibit fibrinogen binding to either 
cell  type.  In  contrast,  several  RGDX  tetrapeptides  were 
identified that inhibited fibrinogen binding to both cell types, 
indicating that an RGD recognition specificity is involved in 
the interaction of this ligand with both cells. As shown in Ta- 
ble I, RGDS, RGDC, RGDV, and RGDF were all found to 
inhibit fibrinogen binding to both endothelial cells and plate- 
lets.  Each of these four tetrapeptides was more potent in in- 
hibiting the interaction of the ligand with platelets than with 
endothelial cells. As the relative potency of the peptides in 
inhibiting the interaction of fibrinogen with the two cell types 
differed considerably (RGDS was 4-fold more active with 
platelets, whereas RGDV was 20-fold more active), the rec- 
ognition  specificity of platelets  and  endothelial  cells  for 
fibrinogen cannot be identical. The most telling example of 
this  disparity  was  observed with the  RGDQ  tetrapeptide. 
This peptide inhibited fibrinogen binding to platelets with an 
IC50 of 45  +  10/~M,  whereas no inhibition of fibrinogen 
binding to endothelial cells was observed at  1 mM. 
As noted in Table I, extension of the RGDF tetrapeptide 
in either the NH2- or COOH-terminal direction resulted in 
peptides that were less potent than the tetrapeptide itself in 
inhibiting fibrinogen binding to platelets. In contrast, such 
extensions resulted in peptides that were more potent than 
the parent tetrapeptide in inhibiting fibrinogen binding to en- 
dothelial cells. The two decapeptides shown in Table I cor- 
respond to the natural amino acid sequences surrounding the 
RGDF sequence at A  a  95-98  of human  fibrinogen (8). 
These extended peptide derivatives were more potent in in- 
hibiting fibrinogen binding to endothelial cells than to plate- 
lets. To emphasize the diffeiential effects of the extended pep- 
tides on fibrinogen binding to the two cell types, the full-dose 
titration inhibition curves of the two decapeptides and the 
parent  RGDF  tetrapeptide  are  presented  in  Fig.  1.  The 
similarity in the effects of the three peptides on fibrinogen 
binding to endothelial cells is apparent and contrasts with 
their markedly different effects on platelets. 
In examining the inhibitory potencies of the RGDX pep- 
tides on fibrinogen binding to platelets, a clear influence of 
the residue in the X  position is observed. In the peptides 
compared in Table I, the more hydrophobic was the residue 
at the fourth position, the more potent was the peptide in in- 
hibiting fibrinogen binding to platelets. This point is illus- 
trated in Fig. 2 in which the hydrophobicity of the residue 
at the X position has been assigned a value, according to the 
scale of Hopp and Woods (22), and plotted against its IC50 
value. A relationship between inhibitory potency and hydro- 
phobicity is observed. Such a relationship is not observed for 
fibrinogen binding to endothelial cells (Table I). For exam- 
ple, RGDV has a more hydrophobic residue at the X position 
than RGDS, but RGDS is more potent in inhibiting fibrino- 
gen binding to endothelial cells. 
The Effects of Fibrinogen ~/-Chain Peptides 
Peptides derived from or corresponding in sequence to the 
extreme COOH-terminal region of the 3' chain of fibrinogen 
have been shown to inhibit the interaction of fibrinogen and 
other adhesive proteins with GPIIb-IIIa (27, 37). A panel of 
peptides corresponding to the sequence of this region was 
synthesized and used, frst, to determine if they interfered 
with fibrinogen binding to endothelial cells and, second, to 
compare the structure-activity relationship of these 3,-chain 
peptides on platelets and endothelial cells. As shown in Table 
II and consistent with previously published data (27, 37), the 
dodecapeptide, which is designated H12 and corresponds to 
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Figure 1. Effect of synthetic peptides corresponding in sequence to the fibrinogen A o~ chain on the binding of fibrinogen to ADP-stimulated 
platelets  (A) and to endothelial  cells (B). Binding assays were performed as described in Materials  and Methods.  Endothelial  cells (2  x 
106 cells/ml)  in PBS, 2% BSA, 1 mM CaCI2, and 1 mM MgCI2 were incubated for 3 h at 37°C in the presence of 0.04/~M  '2sI-fibrinogen. 
Platelets  (2  x  l0  s cells/ml)  in Tyrode's buffer, 2% BSA containing  1 mM CaCI2 were incubated  30 min at 22°C in the presence of 0.1 
/aM t2~I-fibrinogen and 5 #M ADP. Binding  was measured in the presence of various concentrations of RGDF (&), corresponding to the 
A u 95-98 sequence,  or in the presence of two different decapeptides,  corresponding to the natural  sequence  surrounding RGDF in the 
A c~ chain: ILRGDFSSAN (ll) and NIMEILRGDF (•). 
His 400 to Va1411 of the 3' chain of fibrinogen, inhibited the 
binding of fibrinogen  to ADP-stimulated platelets  with  an 
IC5o of 240  +  20 #M.  This level of inhibitory potency was 
maintained as the size of the peptide was reduced from the 
dodecapeptide  down  to the  hexapeptide  K6.  Moreover,  as 
shown in Fig. 3 A, the inhibition produced by these peptides 
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Figure 2. The effect of the hydrophilicity  of the fourth amino acid 
residue at position X on the inhibitory  potency of RGDX tetrapep- 
tides  on the platelet-fibrinogen  interaction.  The IC5o values,  the 
means  from three  separate  experiments,  are plotted  against  the 
hydrophilicity  of the X residue according to the scale of Hopp and 
Woods (22).  The amino acid residues  are (F) phenylalanine,  (V) 
valine,  (C) cysteine,  (Q) glutamine,  and (S) serine. 
exceeded 85 %. Further reduction in the size of the peptides 
to generate the pentapeptide  Q5 resulted in a sharp decline 
in inhibitory activity. No inhibition of fibrinogen binding to 
platelets  was detected with Q5,  A4,  or G3 at  1 mM. 
As shown in Table II, certain 3'-chain peptides,  including 
H12 as well as some of the smaller derivatives, also inhibited 
fibrinogen binding to endothelial cells. Thus, the endothelial 
cell  cytoadhesin shares  a  3' peptide  recognition specificity 
with platelets,  but this  specificity was not identical  for the 
two cell types as most notably demonstrated with the K6 pep- 
tide. This hexapeptide inhibited fibrinogen binding to plate- 
lets with a potency similar to those of the longer 3'-chain pep- 
tides, but it did not inhibit fibrinogen binding to endothelial 
cells at the highest concentration tested.  This difference is 
Table II. Inhibition of  Fibrinogen Binding to 
ADP-stimulated Platelets and to Endothelial  Cells 
by Synthetic Peptides Corresponding  to the 
COOH-Terminus of the Fibrinogen 7 Chain 
IC~o 
Peptides  Platelets  Endothelial  cells 
/zM  /zM 
H12  HHLGGAKQAGDV  240  +  20  140  ±  20 
HI1  HLGGAKQAGDV  240  +  20  360  +  10 
L10  LGGAKQAGDV  170  ::1: 50  130  ::1: 80 
G9  GGAKQAGDV  180  5:  30  330  +  20 
K6  KQAGDV  210  5:: 20  >1,000 
Q5  QAGDV  > 1,000  > 1,000 
A4  AGDV  >1,000 
G3  GDV  >1,000 
125  Binding of  I-fibrinogen to platelets and to endothelial  cells was measured as 
described in Fig.  1. The IC~0 values represent the mean value of four separate 
experiments and were derived from the dose-dependent inhibition curves. 
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Figure 3.  Effects of three selected synthetic  pcptides,  corresponding  to the extreme COOH-terminal sequence of the fibrinogen "y chain, 
on fibrinogen binding to platelets (A) and to endothelial cells (B). The conditions for measuring fibrinogen binding are those described 
in Fig. 1. The selective peptides are H12 (e), HHLGGAKQAGDV;  G9 (A), GGAKQAGDV; and K6 (o), KQAGDV. H, histidine; L, leu- 
cine;  G, glycine; A, alanine; K, lysine; Q, glutamine; D, aspartic acid; and V, valine. 
apparent from the data shown in Fig. 3 B. At 1 mM, K6 failed 
to inhibit endothelial cell binding of fibrinogen, whereas it 
completely inhibited binding of the ligand to platelets. Also 
noted in Fig.  3 B is a difference in the extent of inhibition 
attained at high concentrations of the inhibitory peptides. 
While the inhibition of fibrinogen binding to platelets with 
peptides such as H12 and G9 was complete, these same pep- 
tides only partially inhibited the binding of the ligand to en- 
dothelial cells. Thus, this partial inhibition pattern and the 
marked difference in the inhibitory potency of K6,  distin- 
guish the 3,-chain recognition specificity of endothelial cells 
from platelets. 
The Fine Recognition Specificity of Platelets and 
Endothelial Cells for Fibrinogen 
The above observations indicate that fibrinogen binding to 
endothelial cells and platelets is inhibited by both RGDX and 
"y-chain peptides. In parallel experiments, it was established 
that the two sets of peptides do not have a synergistic effect 
on these reactions. Thus RGDX and 7 peptides produced an 
additive inhibition when mixed at different concentrations 
(data not shown).  However, the precise structural require- 
ments for the inhibitory activity of these peptides differ for 
the two cell types. In subsequent experiments, this difference 
was further explored with RGDF and KQAGDV serving as 
the  prototypic structures  of the  two  peptide  sets.  Single 
amino acid substitution profoundly diminished the inhibitory 
potency of RGDF peptides on fibrinogen binding to platelets. 
As shown in Table III, substitution of a Gly (RGGF) for the 
Asp or a His (HGDF) or a Gin (QGDF) for the Arg resulted 
in a shift in the ICs0 of RGDF from 9/~M to >1 mM. This 
precise  structure-function  relationship  is  consistent  with 
previous studies demonstrating that conservative amino acid 
substitutions at either the Arg,  Gly, or Asp positions also 
resulted in peptides that poorly inhibited fibrinogen binding 
to platelets (38). Thus, conservation of the RGD structure is 
essential for peptides that are potent inhibitors of fibrinogen 
binding to platelets. In contrast, the three substituted pep- 
tides, which were inactive on fibrinogen binding to platelets, 
interfered with fibrinogen binding to endothelial cells and 
were of a potency similar to the parent RGDF peptide (see 
Table Ill). The two peptides in which His or Gin were sub- 
stituted for the Arg residue were as effective as RGDF, and 
the peptide in which the Asp was replaced by a Gly was only 
slightly less inhibitory. These data establish a clear differ- 
ence in the capacity of endothelial cells and platelets to dis- 
tinguish among these related peptide structures. 
A similar conclusion was derived from analysis performed 
with variants of the 7-chain peptide K6.  Substitution of an 
Table IlL Structure-Function  Relationship of  RGD and 
9' Peptides in the Inhibition of 1251-Fibrinogen Binding to 
Platelets and to Endothelial Cells 
IC5o 
Peptides  Platelets  Endothelial  cells 
uM  ,uM 
RGD analogues 
RGDF  9  +  3  150  +  50 
RGGF  >1,000  340  +  40 
HGDF  >1,000  80  +  40 
QGDF  >1,000  150  +  30 
3, analogues 
KQAGDV  210  +  20  >1,000 
RQAGDV  >1,000  600  +  100 
HQAGDV  >1,000  180  +  20 
Binding of '25I-fibrinogen to platelets or to endothelial cells was assayed as 
described in the text or in Fig.  1.  The IC5~ values were obtained from the 
dose-dependent curves of inhibition  and are the mean value of three separate 
experiments. 
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Reactions of  Platelets and Endothelial Cells 
Inhibition 
Platelet  Endothelial  cell  Endothelial  cell 
Peptides  aggregation  attachment  spreading 
%  % 
None  0  0  +  + + + 
RGDF  100  84  +  6  0 
HGDF  0  38  +  8  0 
KQAGDV  84  ±  7  7  +  5  + + 
HQAGDV  0  0  +  + 
Endothelial cell attachment and spreading were estimated in medium 199, 2% 
BSA  in the  presence of a 2-mM concentration  of each peptide.  Aggregation 
was measured  with  washed  platelets  suspended  in  the  medium  199  in  the 
presence of 2 mM peptides and 20 #M  ADP. The scale used to estimate en- 
dothelial cell spreading was based on double immunofluorescent localization of 
action.  Maximal spreading was noted (+ + + +) and corresponded  to Fig. 4 
A;  incomplete  spreading  was noted  (++) and  corresponded  to  Fig.  4  B; 
minimal spreading was noted (0) and corresponded  to Fig. 4 C. 
Arg (RQAGDV) or a His (HQAGDV) for the Lys residue at 
the NH2 terminus yielded peptides that no longer inhibited 
fibrinogen binding to platelets; i.e., these replacements de- 
creased  inhibitory  potency  at  least  fivefold.  In  contrast, 
these  variant  peptides  inhibited  fibrinogen binding  to  en- 
dothelial cells, even though the parent K6 peptide was inac- 
tive. HQAGDV was at least fivefold more potent in inhibiting 
fibrinogen binding to endothelial cells than to platelets and 
was at least fivefold more potent than K6 on endothelial cells. 
Effects of the Peptides on Platelet and Endothelial 
Cell Function 
To place  the  above described  inhibition experiments  in  a 
functional perspective, the effects of selective peptides on 
fibrinogen-dependent platelet  aggregation  and  endothelial 
cell adhesion and spreading were examined. To compare the 
relative potency of each peptide under the same conditions, 
both cells were suspended in medium  199. The results ob- 
mined with platelets in medium 199 (Table IV) were identical 
to those obtained when the cells were washed and suspended 
in  the  routine  tyrode-2%  albumin  buffer.  Adhesion  and 
spreading of endothelial cells were performed with fibronec- 
tin-depleted fibrinogen. Spreading was estimated with a dou- 
ble  immunofluorescent staining  procedure  using  antiactin 
antibodies. A typical pattern in the absence of peptides was 
shown in Fig. 4 A: extensive spreading led to stress fiber or- 
ganization. As noted in Table IV and Fig. I, RGDF inhibited 
fibrinogen binding on platelets and platelet aggregation. This 
peptide on endothelial cells also inhibited fibrinogen bind- 
ing,  adhesion,  and  spreading.  The inhibition curves were 
dose dependent (Fig. 5). HGDF, which inhibited fibrinogen 
binding to endothelial cells (Fig. 5) but not to platelets (Table 
III),  had  no effect on platelet aggregation (Table IV).  As 
shown in Fig. 5, HGDF and RGDF produced the same dose- 
dependent inhibition curves for the binding of fibrinogen to 
endothelial cells,  but the adhesive properties of these two 
peptides were quite different. While RGDF inhibited endo- 
thelial  cell adhesion with a  similar dose-dependent curve, 
HGDF had a weaker effect (Fig. 5).  HGDF, however, pro- 
duced a complete inhibition of endothelial cell spreading as 
shown in Fig. 4  C,  where the rounded cells without stress 
fiber organization were shown. Thus RGDF was a potent in- 
hibitor of endothelial cell attachment and spreading, whereas 
HGDF was only a potent inhibitor of spreading. This differ- 
ence suggests that the mechanisms for ligand binding in the 
attachment and spreading reactions are probably different. 
Two different hexamers from the 7-chain series were also 
tested. KQAGDV, at 2-mM concentration, produced an al- 
most complete inhibition of the aggregation of washed plate- 
lets but had no effect on endothelial cell adhesive reactions 
(Table IV). The modified peptide, HQAGDV, which was in- 
active on fibrinogen binding to platelets, did not inhibit plate- 
let  aggregation.  This  peptide,  which  inhibited  fibrinogen 
binding on endothelial cells, although to a lesser extent than 
RGDF, did not modify endothelial cell attachment but pro- 
duced  a  slight inhibition of endothelial  cell  spreading  on 
fibrinogen.  Partial stress fiber organization was formed in 
the cells shown in Fig. 4 B. 
Figure 4. Actin microfilament bundle organization in endothelial cells cultured for 2 h on fibronectin-depleted fibrinogen substrates in the 
presence or in the absence of inhibitory peptides. Cells were fixed and stained immunofluorescently with human antiactin antibodies. A 
represents extensive cell spreading and stress fiber formation (arrow) in the absence of peptides (+ + + +). B represents partial spreading 
and minimal actin bundles (arrows) in the presence of 2 mM of the peptides KQAGDV or HQAGDV (+ +).  C shows no spreading and 
no microfilarnent bundles in the presence of 2 mM of the peptide HGDF (0). Bars, 10/~M. 
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Figure  5.  Comparison of the 
inhibitory capacity of the pep- 
tides RGDF and HGDF to in- 
hibit, respectively, fibrinogen 
binding to endothelial cells and 
adhesion to fibrinogen-coated 
dishes. The binding and the ad- 
hesion assays were performed 
as described in Materials and 
Methods. RGDF in the adhe- 
sion (zx) and binding (-) as- 
says had a similar inhibitory 
effect, whereas HGDF has an 
appreciable effect in the bind- 
ing assay (I), but a weak ef- 
fect in the adhesion assay ([]). 
Discussion 
The platelet fibrinogen receptor is the membrane glycopro- 
tein GPIIb-IIIa, a calcium-dependent heterodimer that be- 
longs to the RGD adhesion receptor superfamily. In addition 
to fibrinogen, this receptor interacts with two other RGD- 
containing proteins, fibronectin (13, 36) and von WiUebrand 
factor (12, 45), suggesting that GPIIb-IIIa has a broad recog- 
nition specificity. Two sets of synthetic peptides have been 
shown to inhibit the binding of these adhesive proteins to 
GPIIb-IIIa  and  their  related  adhesive  reactions:  peptides 
containing the sequence RGD, common to all the interactive 
ligands, and peptides corresponding to the COOH terminus 
of the fibrinogen 3' chain with the  structure HHLGGAK- 
QAGDV which is only present within the fibrinogen mole- 
cule. Both sets ofpeptides interact with GPIIb-IIIa at specific 
and related sites (9,  28, 47).  The molecular entity for the 
fibrinogen binding sites on endothelial cells has not yet been 
clearly identified. However, recent findings have indicated 
that the endothelial cell binding site for fibrinogen also has 
an RGD specificity and that certain GPIIb-IIIa antibodies 
can inhibit this interaction (29). To compare the specificity 
of the endothelial binding sites with that of GPIIb-IIIa, we 
have analyzed the structure-function relationship of  both sets 
of peptides in the two cellular systems. 
Consistent  with  previously published  observations con- 
cerning other RGD adhesion receptors (33,  35), the tripep- 
tide RGD itself was inefficient in inhibiting the binding of 
fibrinogen  to  platelets  and  to  endothelial  cells.  A  fourth 
amino acid residue at position X in the sequence RGDX was 
necessary for the synthetic peptides to express inhibitory ac- 
tivity on both cells. With platelets, the more hydrophobic this 
residue was, the more potent the RGDX peptide was. For in- 
stance, RGDF was six times more potent than RGDS. This 
structure-function  relationship  was  not  observed  on  en- 
dothelial cells as  RGDF and  RGDS  were equally potent. 
These results are consistent with the recent findings that the 
amino acid residues at position X  may considerably influ- 
ence the stereochemistry and potency of RGDX peptides in 
inhibiting RGD receptors on other cells (34). A differential 
effect was observed when the arginine residue in RGDF was 
replaced by a more acidic residue (HGDF) or a neutral resi- 
due (QGDF). These peptides had contrasting effects on fi- 
brinogen binding to the two cell types. 
The shortest 3,-chain  peptide that was active on platelets 
was the hexapeptide, KQAGDV, which corresponds to Lys 
406 to Val 411 of the 3, chain of fibrinogen. This peptide in- 
hibited fibrinogen binding to platelets with an IC50 similar 
to that of the dodecapeptide, HHLGGAKQAGDV. This re- 
sult  is  somewhat different from  those obtained by  Kloc- 
zewiack et al. (27), who have shown that the dodecapeptide 
was more potent than the heptapeptide AKQAGDV, and our 
own previous study (37), in which the nonapeptide was found 
to be less active than the dodecapeptide. At the present time, 
we have no explanation for these discrepancies; however, all 
peptides tested have now been synthesized on multiple occa- 
sions and have consistently given the results shown in the 
present study. Again, it is noteworthy that the amino acid res- 
idue present at the COOH terminus of the hexapeptide K6 
is a Val, which has hydrophobic properties, and that this pep- 
tide was inactive on endothelial cells. However, when the ly- 
sine residue was replaced by the more acidic histidine resi- 
due, the activity was diminished for platelets and enhanced 
for endothelial cells. 
From  these  results,  the  following  conclusions  can  be 
drawn: (a) both RGDX and v-chain peptides inhibit the bind- 
ing of fibrinogen to platelets and to endothelial cells; (b) a 
clear influence of the residue at the COOH position and the 
Tranqui et al. Structural Requirements for Fibrinogen Binding  2525 NH2 position of each peptide set can be demonstrated on 
the two cell types; (c) although RGDX and 3' peptides have 
a differential effect on platelets and on endothelial cells, their 
structural requirements for inhibiting fibrinogen binding to 
one cell type appear to be consistent; for instance, HGDF 
and HQAGDV were both inactive on platelets but were potent 
inhibitors on endothelial cells; and (d) inhibition of fibrin- 
ogen binding correlated with an inhibition of the adhesive 
reactions of each cell type. This relationship between inhibi- 
tion of binding and function is, however, more complex for 
endothelial cells. In previous studies, we have shown that the 
plasmin degradation product fragment D of high molecular 
weight, which contains the COOH-terminal domain of the 
3' chain, did not significantly  inhibit the binding of fibrinogen 
to endothelial cells. The 3'-chain sequence may have an affin- 
ity lower than the RGDF sequence that is present in the fi- 
brinogen Act chain for endothelial cells. It is noteworthy that 
none of the 3,-chain peptides completely inhibited binding of 
fibrinogen to endothelial cells. Accordingly, the fibrinogen 
recognition site on endothelial cells may interact predomi- 
nantly with the RGDF sequence in the A c~ chain. The obser- 
vation that RGDF-containing decapeptides with the adjacent 
sequence from the A c~ chain were more potent than RGDF 
itself supports this hypothesis. 
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